{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T01:53:56Z","timestamp":1767146036729,"version":"build-2238731810"},"update-to":[{"DOI":"10.1016\/j.dld.2025.04.040","type":"withdrawal","label":"Withdrawal","source":"publisher","updated":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000}},{"DOI":"10.1016\/j.dld.2024.12.014","type":"withdrawal","label":"Withdrawal","source":"publisher","updated":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000}}],"reference-count":3,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","dldjournalonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.dld.2025.05.016","type":"journal-article","created":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T02:22:26Z","timestamp":1748744546000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["WITHDRAWN: Personalized bevacizumab dosing in metastatic colorectal cancer: Statistical considerations for a phase III randomized trial"],"prefix":"10.1016","author":[{"given":"Yue","family":"Lv","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaying","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.dld.2025.05.016_bib0001","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.dld.2025.02.002","article-title":"Bevacizumab-based chemotherapy adaptive to pharmacokinetic of bevacizumab in first-line treatment of patients with unresectable metastatic colorectal cancer: a double-blind, multicenter, randomized phase III trial study (PHARBEVACOL trial)","volume":"57","author":"Lecomte","year":"2025","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.dld.2025.05.016_bib0002","article-title":"County incarceration rate and stroke death: a cross-sectional study of the influence of physical environment, health care access, and community mental distress","volume":"13","author":"Larrabee","year":"2025","journal-title":"Am Heart Assoc"},{"key":"10.1016\/j.dld.2025.05.016_bib0003","article-title":"Association between visceral adiposity index and all-cause and cardiovascular mortality in the non-elderly adults","volume":"16","author":"Zhang","year":"2025","journal-title":"Front Endocrinol"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S159086582500787X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S159086582500787X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T18:05:39Z","timestamp":1751565939000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S159086582500787X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":3,"alternative-id":["S159086582500787X"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2025.05.016","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"WITHDRAWN: Personalized bevacizumab dosing in metastatic colorectal cancer: Statistical considerations for a phase III randomized trial","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2025.05.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2025.04.040","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2024.12.014","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}